Procjena stadija bolesti ključna je u odabiru optimalnog načina liječenja. Kvaliteta transuretralne resekcije i patološka evaluacija reseciranog tkiva tumora temelji su procjene stadija bolesti. Ponovna transuretralna resekcija indicirana je kod nepotpune resekcije tumora te kod bolesnika s visokorizičnim nemišićnoinvazivnim rakom mjehura. Najnovija saznanja podupiru agresivan kirurški tretman invazivnog karcinoma mjehura. Stratifikacija rizika temelji se na nalazu patologa pri početnoj transuretralnoj resekciji. Bolesnici s bolesti ograničenom na organ i negativnim limfnim čvorovima imaju izvrsne izglede za dugoročno preživljavanje.The staging of bladder cancer is crucial for optimal management of the disease. Quality of the transurethral resection of bladder carcinoma and pathologic evaluation of resected tissue by a specialized uropathologist is the cornerstone of bladder carcinoma staging. Restaging transurethral resection is indicated in high-risk non-invasive cancers and also if incomplete resection is demonstrated or suspected. Evidence supports early, aggressive surgical management of invasive bladder cancer. Risk stratification of patients with bladder cancer based on pathologic features at initial transurethral resection or at recurrence can select those patients most appropriate for early radical cystectomy. In patients with organ-confined, lymph node-negative urothelial bladder carcinoma, excellent long-term survival rates can be achieved
